Rotational Atherectomy or Balloon-Based Techniques to Prepare Severely Calcified Coronary Lesions.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
26 09 2022
Historique:
received: 27 03 2022
revised: 21 07 2022
accepted: 25 07 2022
entrez: 22 9 2022
pubmed: 23 9 2022
medline: 28 9 2022
Statut: ppublish

Résumé

The comparative efficacy of percutaneous techniques for the preparation of calcified lesions before stenting remains poorly studied. This study sought to compare the performance of up-front rotational atherectomy (RA) or balloon-based techniques before drug-eluting stent implantation in severely calcified coronary lesions as assessed by angiography and optical coherence tomography (OCT). Patient-level data from the PREPARE-CALC (Comparison of Strategies to Prepare Severely Calcified Coronary Lesions) and ISAR-CALC (Comparison of Strategies to Prepare Severely Calcified Coronary Lesions) randomized trials were pooled. The primary endpoint was stent expansion as assessed by OCT imaging. The secondary endpoints included stent eccentricity, stent asymmetry, angiographic acute lumen gain, strategy success and in-hospital occurrence of cardiac death, target vessel myocardial infarction, and repeat revascularization. Among 274 patients originally randomized, 200 participants with available OCT data after lesion preparation with RA (n = 63), a modified balloon (MB, n = 103), or a super high-pressure balloon (n = 34) before stenting were analyzed. The use of RA versus MB or a super high-pressure balloon led to comparable stent expansion (73.2% ± 11.6% vs 70.8% ± 13.6% vs 71.8% ± 12.2%, P = 0.49) and stent asymmetry (P = 0.83). Compared with RA or MB, a super high-pressure balloon was associated with less stent eccentricity (P = 0.03) with a numerically higher acute lumen gain, albeit not significantly different (P = 0.08). Strategy success was more frequent with RA versus MB (P = 0.002) and numerically more frequent with RA versus a super high-pressure balloon (P = 0.06). Clinical outcomes did not differ between groups. In patients with severely calcified lesions undergoing drug-eluting stent implantation, lesion preparation with RA, MB, or a super high-pressure balloon was associated with comparable stent expansion. A super high-pressure balloon is associated with less stent eccentricity, whereas strategy success is more frequent with RA.

Sections du résumé

BACKGROUND
The comparative efficacy of percutaneous techniques for the preparation of calcified lesions before stenting remains poorly studied.
OBJECTIVES
This study sought to compare the performance of up-front rotational atherectomy (RA) or balloon-based techniques before drug-eluting stent implantation in severely calcified coronary lesions as assessed by angiography and optical coherence tomography (OCT).
METHODS
Patient-level data from the PREPARE-CALC (Comparison of Strategies to Prepare Severely Calcified Coronary Lesions) and ISAR-CALC (Comparison of Strategies to Prepare Severely Calcified Coronary Lesions) randomized trials were pooled. The primary endpoint was stent expansion as assessed by OCT imaging. The secondary endpoints included stent eccentricity, stent asymmetry, angiographic acute lumen gain, strategy success and in-hospital occurrence of cardiac death, target vessel myocardial infarction, and repeat revascularization.
RESULTS
Among 274 patients originally randomized, 200 participants with available OCT data after lesion preparation with RA (n = 63), a modified balloon (MB, n = 103), or a super high-pressure balloon (n = 34) before stenting were analyzed. The use of RA versus MB or a super high-pressure balloon led to comparable stent expansion (73.2% ± 11.6% vs 70.8% ± 13.6% vs 71.8% ± 12.2%, P = 0.49) and stent asymmetry (P = 0.83). Compared with RA or MB, a super high-pressure balloon was associated with less stent eccentricity (P = 0.03) with a numerically higher acute lumen gain, albeit not significantly different (P = 0.08). Strategy success was more frequent with RA versus MB (P = 0.002) and numerically more frequent with RA versus a super high-pressure balloon (P = 0.06). Clinical outcomes did not differ between groups.
CONCLUSIONS
In patients with severely calcified lesions undergoing drug-eluting stent implantation, lesion preparation with RA, MB, or a super high-pressure balloon was associated with comparable stent expansion. A super high-pressure balloon is associated with less stent eccentricity, whereas strategy success is more frequent with RA.

Identifiants

pubmed: 36137691
pii: S1936-8798(22)01482-0
doi: 10.1016/j.jcin.2022.07.034
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1864-1874

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures The PREPARE-CALC trial was an investigator-initiated trial, which was financed by the Heart Center, Segeberger Kliniken GmbH, Bad Segeberg, Germany. The ISAR-CALC trial was an investigator-initiated trial, which was supported by a research grant from SIS Medical AG and Boston Scientific. Dr Rheude has received speaker fees from SIS Medical AG. Dr Allali has received speaker/proctoring honoraria from Boston Scientific and Biotronik. Dr Cuculi has received speaker and consulting fees from Abbott Vascular and SIS Medical AG. Dr Kufner has received speaker and consulting fees from AstraZeneca, Bristol Myers Squibb, and Translumina not related to the current work. Dr Bossard has received speaker and consulting fees from Abbott Vascular and SIS Medical AG. Dr Joner has received lecture fees and research grants from Edwards Lifesciences and Boston Scientific; and is a consultant for Biotronik and Orbus Neich. Dr Byrne has received research funding to the institution from Abbott Vascular, Biosensors, and Boston Scientific. Dr Cassese has received lectures/proctoring honoraria from SIS Medical AG; and has received research funding to the institution from SIS Medical AG and Boston Scientific for the conduct of the ISAR-CALC trial. Dr Abdel-Wahab reports that his hospital received speaker honoraria and/or consulting fees on his behalf from Medtronic and Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Tobias Rheude (T)

Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Munich, Germany.

Sean Fitzgerald (S)

Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany; School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.

Abdelhakim Allali (A)

Heart Center, Segeberger Kliniken, Bad Segeberg, Germany.

Kambis Mashayekhi (K)

Division of Cardiology and Angiology II, University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany.

Tommaso Gori (T)

Medizinische Klinik und Poliklinik, Universitätsmedizin Mainz, Mainz, Germany.

Florim Cuculi (F)

Department of Cardiology, Kantonspital Luzern, Switzerland.

Sebastian Kufner (S)

Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Munich, Germany.

Rayyan Hemetsberger (R)

Klinik für Kardiologie und Angiologie, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil Bochum, Bochum, Germany.

Dmitriy S Sulimov (DS)

Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany.

Himanshu Rai (H)

Cardiovascular Research Institute Dublin, Mater Private Network, Dublin, Ireland; School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.

Mohamed Ayoub (M)

Division of Cardiology and Angiology II, University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany.

Matthias Bossard (M)

Department of Cardiology, Kantonspital Luzern, Switzerland.

Erion Xhepa (E)

Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Munich, Germany.

Massimiliano Fusaro (M)

Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Munich, Germany; Klinik für Kardiologie und Angiologie, Zollernalb-Klinikum, Albstadt, Germany.

Ralph Toelg (R)

Heart Center, Segeberger Kliniken, Bad Segeberg, Germany.

Michael Joner (M)

Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Munich, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Munich Heart Alliance, Munich, Germany.

Robert A Byrne (RA)

Cardiovascular Research Institute Dublin, Mater Private Network, Dublin, Ireland; School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.

Gert Richardt (G)

Heart Center, Segeberger Kliniken, Bad Segeberg, Germany.

Adnan Kastrati (A)

Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Munich, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Munich Heart Alliance, Munich, Germany.

Salvatore Cassese (S)

Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Munich, Germany. Electronic address: cassese@dhm.mhn.de.

Mohamed Abdel-Wahab (M)

Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH